Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

pharmafile | October 8, 2019 | News story | Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma 

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor T cell (CAR-T) therapy Yescarta (axicabtagene ciloleucel) on the NHS in Scotland.

Following the decision, patients will be able to receive the therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), in adult patients who have tried two or more lines of systemic therapy.

The ruling marks the second NHS approval of a CAR-T therapy in Scotland, following Novartis’ Kymriah (tisagenlecleucel) earlier this year for the treatment of relapsed/refractory DLBCL in adults and acute lymphoblastic leukaemia.

“This is further good news for people affected by lymphoma as it means there is wider access to CAR T cell therapy in Scotland. It is important for people affected by DLBCL and particularly significant for people affected by primary mediastinal B-cell lymphoma, for whom CAR T cell therapy would not otherwise be available in Scotland,” remarked Stephen Scowcroft, Director of Operations and External Affairs at Lymphoma Action.

General Manager, Gilead UK & Ireland’s General Manager Hilary Hutton-Squire also remarked: “This is an important day for patients in Scotland with certain aggressive forms of blood cancer. Yescarta is an individualised cell therapy that provides a valuable treatment option for patients who have exhausted other therapies, meaning they may have just months left to live, potentially changing their outcomes.” 

Matt Fellows

Related Content


UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content